Clinical-stage drug developer QurAlis Corporation raised USD 88 million in an oversubscribed Series B funding round led by EQT Life Sciences, with participation from LSP Dementia Fund, Sanofi Ventures, Droia Ventures, the ALS Investment Fund, and existing investors. This brings the total funds raised to USD 143.5 million. 

The funds raised will be used to expedite the clinical development of the company’s main product candidates, QRL-201 and QRL-101, which are intended to treat amyotrophic lateral sclerosis (ALS). Additionally, the funds will be used to support the company's research projects, as well as to advance the development of new therapies that aim to target specific components of ALS and related frontotemporal dementia (FTD) pathology. 

QurAlis is a biotech company that is focused on developing precision medicine for ALS  and related neurodegenerative diseases. The company has a total of five drugs in development, one of which is QRL-201, a treatment that restores the production of the STMN2 protein in individuals with ALS. Another drug, QRL-101, aims to address the progression of hyperexcitability-related diseases in ALS patients. Both QRL-201 and QRL-101 are currently undergoing Phase 1 clinical trials. The creators of QurAlis are a group of neurodegenerative biologists from Harvard University and Harvard Medical School.